C4 Therapeutics, Inc. (CCCC) intrinsic value & 10-year financials
C4 Therapeutics, Inc. (CCCC) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 20.1% a year to $35.9M, with an average return on invested capital of -5.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.77
- Market cap
- $229.2M
- Revenue (FY2025)
- $35.9M
- Revenue growth (8-yr CAGR)
- 20.1%
- ROIC (10-yr avg)
- -5.8%
- Free cash flow (FY2025)
- -$99.3M
CCCC 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $35.9M | -$105.0M | -$1.27 | -$99.3M | -320.5% | -50.5% |
| FY2024 | $35.6M | -$105.3M | -$1.52 | -$65.3M | -336.1% | -59.0% |
| FY2023 | $20.8M | -$132.5M | -$2.67 | -$108.5M | -669.8% | -52.7% |
| FY2022 | $31.1M | -$128.2M | -$2.62 | -$111.4M | -416.6% | -37.2% |
| FY2021 | $45.8M | -$83.9M | -$1.82 | -$88.2M | -179.4% | -34.5% |
| FY2020 | $17.6M | -$66.3M | — | -$67.9M | -344.0% | 174.3% |
| FY2019 | $11.9M | -$34.1M | — | $54.3M | -296.7% | 18.7% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
C4 Therapeutics, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
C4 Therapeutics, Inc. has historically struggled to out-earn its cost of capital, averaging just -30.5% ROIC.
C4 Therapeutics, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, C4 Therapeutics, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-42.18 per share.